In 2022, the gene, cell, and RNA therapy pipeline from preclinical to pre-registration grew by 7%, bringing the total number of therapies in development to 3,726. More than half (55%) of those are gene therapies, including genetically modified therapies like CAR T cell therapies. The remainder are non-genetically modified cell therapies (22%) and RNA therapies (23%).
In the gene therapy pipeline, oncology and rare diseases remain the top areas of development overall and in the clinic. Oncology and rare diseases are also the top areas of development in the overall pipeline of non-genetically modified cell therapies. Rare diseases and anti-infective therapies remain the top two targeted areas by RNA therapies.
Gain more insight from the 2022 fourth quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).